Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Advagraf-based immunosuppression with or without sirolimus in kidney transplant recipients
2010-019639-37Phase 4Completed
- Sponsor
- Astellas Pharma
- Start
- Nov 2010
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tacrolimus and sirolimus in kidney transplant immunosuppression (2 arms), sponsored by Astellas Pharma. Primary endpoint: Glomerular filtration rate by iohexol clearance at week 52. Started Nov 2010; status: completed.
02
Drugs
tacrolimussirolimus
03
Conditions
kidney transplant immunosuppression
Beyond the preview
Go deeper on 2010-019639-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019639-37.